This is the ELN for the nitroimidazole resistance clusters analysis.
Mapping delamanid-resistance SNPs onto a phylogeny of all samples in the TB Portals database identified a cluster of ~20 samples with the ddn W88* mutation. This mutation is recognized as conferring resistance to nitroimidazole drugs, including delamanid and pretomanid. There were also two samples that did not group with the main cluster that had this mutation. These two instances were found to be from a different Mtb taxonomic lineage. Examination of the literature identified further samples with this mutation that also clustered with the initally identified samples.
After a presentation of preliminary results at the ESM 2023 conference a collaboration was initiated by a European colleague. He sent out an inquiry to multiple European TB reference laboratories to check their sample stocks for instances of the ddn W88* mutation. This, in combination with a search for samples with this mutation in the TB Profiler database identified >100 additional samples.